Parexel

Parexel International is a leading drug research contract research organization (CRO) headquartered in the United States, with nearly 70 offices worldwide and more than 22,000 employees, serving clients in over 100 countries. Founded in 1982, Parexel has been committed over more than four decades to becoming a premier provider of new medical therapy development and commercialization services for the global biopharmaceutical and medical device industries, achieving outstanding results. Currently, we offer the most comprehensive clinical-stage drug development services in the CRO field worldwide, including the formulation and planning of new drug development strategies, execution and integration of international clinical trials, monitoring of clinical trials, clinical trial data processing, statistical analysis of clinical research, clinical trial summaries and statistical reports, clinical trial auditing services, clinical trial supply and logistics services, clinical electronic data capture, clinical medical information management systems, new drug registration affairs, and consultation on international clinical trial regulations. Our integrated solutions combine global regulatory expertise, Phase I-IV clinical research services, integrated electronic clinical technology capabilities, and commercialization services to help clients drive their entire R&D process more smoothly, economically, and efficiently. In recent years, Parexel has invested in digital architecture, domain expertise, and AI solutions, launching ParexelAI — an innovative proprietary service combining operational excellence and cutting-edge AI technology, adopting a human-led AI approach to ensure expert involvement, and collaborating with various AI strategic enterprises to enhance efficiency and quality, helping clients accelerate clinical development and bring drugs to patients faster.